HypothesisPercutaneous angioplasty would provide a durable alternative to surgical revision in the treatment of infrainguinal vein graft stenosis.DesignOutcome
PhD in Cardiovascular Sciences. The application of spatial transcriptomics to the study of accelerated atherosclerosis in human vein grafts. Supervisors Mr Mustafa Zakkar, Prof Gavin Murphy
The action of MMPs has been linked to the pathological remodeling of blood vessels that constitutes the basis for cardiovascular conditions with significant mortality and morbidity. Specifically, MMP-9 has been associated with the development of lesions after vascular surgical interventions,12 appears to have a role in vein graft occlusion after coronary bypass surgery,13,14⇓ and seems to be associated with acute vascular syndromes,15,16⇓ suggesting that MMP-9 may be an attractive target for therapeutic intervention. However, lack of specificity, poor oral bioavailability, and unrelated side effects of currently available synthetic inhibitors do not allow the proper demonstration of MMP-9 involvement in pathological arterial remodeling. We thus decided to investigate the role of MMP-9 in arterial remodeling by using targeted genetic disruption of MMP-9 gene, which results in complete loss of MMP-9 expression and activity,6 and the mouse carotid artery flow cessation model. In spite of its ...
Saphenous Vein Bypass Graft Disease Hardcover Books- Buy Saphenous Vein Bypass Graft Disease Books online at lowest price with Rating & Reviews , Free Shipping*, COD. - Infibeam.com
TY - JOUR. T1 - A New Treatment Strategy for Saphenous Vein Graft Lesions?. T2 - Letting it Go ∗. AU - Brilakis, Emmanouil S.. AU - Banerjee, Subhash. AU - Burke, M. Nicholas. PY - 2018/5/8. Y1 - 2018/5/8. KW - coronary artery bypass graft surgery. KW - native coronary artery. KW - percutaneous coronary intervention. KW - saphenous vein graft. UR - http://www.scopus.com/inward/record.url?scp=85046542322&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=85046542322&partnerID=8YFLogxK. U2 - 10.1016/j.jacc.2018.03.457. DO - 10.1016/j.jacc.2018.03.457. M3 - Editorial. C2 - 29724351. AN - SCOPUS:85046542322. VL - 71. SP - 1983. EP - 1985. JO - Journal of the American College of Cardiology. JF - Journal of the American College of Cardiology. SN - 0735-1097. IS - 18. ER - ...
In the present study, the expression and causal involvement of MCP-1 in the development of IH in a mouse in vivo or a human ex vivo model of vein graft disease is demonstrated. MCP-1 expression was shown to be present in the murine vein graft and was also detectable in a HSV organ culture. Blocking the CCR2/MCP-1 pathway, using the receptor antagonist 7ND-MCP-1, resulted in a reduced vein graft thickening in both the murine vein graft and in HSV segments. Furthermore, we demonstrate that reduced vein graft thickening, besides the effect on monocyte chemotaxis, is caused by a direct antiproliferative effect of 7ND-MCP-1 on vascular SMCs.. Vein graft thickening attributable to development of IH and accelerated atherosclerosis is the major limitation in the long-term survival of patent vein grafts. The mechanism of vein graft thickening development is largely unknown, but it is assumed that it is caused by an inflammatory response to damage of the graft.9,10. MCP-1 is a well-known proinflammatory ...
Objectives: The mechanisms of early vein graft failure after coronary artery bypass graft (CABG) surgery remains unclear. We hypothesized that insufficiency of DNA repair pathway in human vein graft is related to early graft failure.. Methods: Human internal mammary arteries (IMA) and saphenous veins (SV) samples were obtained from coronary artery bypass grafting surgery. Among 118 SV segments, there was 9% vein grafts had early grafting failure within 7 days which is determined by Multichannel-EKG-gated CT angiography (Philips Medical). In contrast, there was no early graft failure in 28 IMA grafts. Human IMA or SV segments (1 X 1 mm) were incubated in organ culture system in the absence or presence of 1% H2O2 for 24 hours with 20% O2. DNA damage was determined by 8-oxoG staining, and DNA repair pathways were investigated by MYH (DNA mismatch repair) immunohistochemical staining. Apoptotic level was evaluated by TUNEL staining and DNA gel analysis. The positive staining rate was determined by ...
TY - JOUR. T1 - Macrophage Notch Ligand Delta-Like 4 Promotes Vein Graft Lesion Development. T2 - Implications for the Treatment of Vein Graft Failure. AU - Koga, Jun Ichiro. AU - Nakano, Toshiaki. AU - Dahlman, James E.. AU - Figueiredo, Jose Luiz. AU - Zhang, Hengmin. AU - Decano, Julius. AU - Khan, Omar F.. AU - Niida, Tomiharu. AU - Iwata, Hiroshi. AU - Aster, Jon C.. AU - Yagita, Hideo. AU - Anderson, Daniel G.. AU - Keith Ozaki, C.. AU - Aikawa, Masanori. PY - 2015/11/1. Y1 - 2015/11/1. N2 - Objective-Despite its large clinical impact, the underlying mechanisms for vein graft failure remain obscure and no effective therapeutic solutions are available. We tested the hypothesis that Notch signaling promotes vein graft disease. Approach and Results-We used 2 biotherapeutics for Delta-like ligand 4 (Dll4), a Notch ligand: (1) blocking antibody and (2) macrophage-or endothelial cell (EC)-targeted small-interfering RNA. Dll4 antibody administration for 28 days inhibited vein graft lesion ...
Despite advances in endovascular strategies, surgical infrainguinal lower limb revascularization remains the gold standard treatment for critical lower limb ischemia and disabling claudication. Maintaining patency of infrainguinal vein bypass grafts has been a challenging task for vascular surgeons as they are prone to developing stenoses which may precipitate failure of the bypass. Duplex ultrasound scanning has evolved as the investigation of choice to identify vein graft lesions but graft surveillance programs using this technique remain controversial. The rationale for graft surveillance is that intervention in a patent but failing graft results in improved long-term patency and limb salvage rates compared to rescue of an occluded graft. The six-week postoperative Duplex ultrasound scan is important in identifying flow abnormalities that can predict the natural history of a vein graft and the outlook for the limb in the medium term. There are multiple factors influencing vein graft failure, ...
This investigation reveals that human vein grafts very soon after CABG show distinct changes. These changes are characterised by loss of surface lining endothelial cells, insudation of blood corpuscular elements such as polymorphonuclear leucocytes and monocytes, admixed with a fibrin-platelet thrombus, the appearance of vimentin positive, actin negative spindle shaped cells, and absence of actin positive SMCs in the pre-existent media topographically related to the sites of neointimal reaction. These observations allow speculations as to the mechanisms involved in neointimal thickening.. Denudation of the surface endothelial cell lining appears to be a crucial factor, and its extent and severity may eventually determine graft patency. Loss of endothelial cells, as observed in veins 2-9 days after grafting, is accompanied by insudation with polymorphonuclear leucocytes, blood monocytes, and T lymphocytes. To this end our observations fit with previous experimental works. Brody and colleagues11 ...
The hemodynamics of 56 femorodistal saphenous vein bypasses (in situ [n = 53] or reversed [n = 3]) identified to have residual or recurrent graft stenoses were characterized with Doppler-derived blood flow velocity and resting limb systolic pressure measurements. The magnitude and configuration of the graft blood flow velocity waveform were the best predictors of graft stenosis. Transformation of the graft blood flow velocity waveform from a triphasic to a monophasic or biphasic configuration coupled with a low (less than 45 cm/sec) or decrease (greater than 30 cm/sec) in peak systolic blood flow velocity relative to initial postoperative levels reliably predicted the presence of a remote occlusive lesion. In 20 (36%) of the 56 limbs, the ankle-brachial systolic pressure index (ABI) did not identify graft stenosis. The low sensitivity of ABI in the identification of graft stenosis was due to insignificant decrease (less than 0.15) of ABI (n = 11), incompressibility of the tibial arteries (n = 6), or
TY - JOUR. T1 - Diffusa ectasia e aneurisma focale di un by-pass venoso aorto-coronarico. AU - Lucreziotti, Stefano. AU - Sponzilli, Carlo. AU - Castini, Diego. AU - Salerno, Diego. AU - Bosotti, Laura. AU - Lombardi, Federico. PY - 2007/4. Y1 - 2007/4. N2 - Saphenous vein graft disease is a continuum process which develops from the very early post-surgical period. Although progressive obstruction is the most common feature of SVG disease, severe dilatation with patterns of diffuse ectasia, aneurysm, or pseudoaneurysm may rarely occur. The present article describes a case of an aorto-coronary vein graft presenting an angiographic pattern of diffuse ectasia with a focal aneurysm.. AB - Saphenous vein graft disease is a continuum process which develops from the very early post-surgical period. Although progressive obstruction is the most common feature of SVG disease, severe dilatation with patterns of diffuse ectasia, aneurysm, or pseudoaneurysm may rarely occur. The present article describes a ...
We have shown for the first time to our knowledge that even in the absence of atherosclerosis, the majority of vein graft neointimal and medial cells derive from precursors that are extrinsic to the vein at the time of grafting. We have also provided the first evidence that the arterializing vein graft wall develops largely from focal expansions of progenitor cells, which originate within and outside of the vein graft at the time of implantation. Finally, we have shown that endothelial remodeling of vein grafts is accomplished by the expansion of graft-intrinsic as well as graft-extrinsic cells, and that BM-derived cells participate in this process. Importantly, these novel insights into vein graft biology derive from a murine vein graft system that we have shown to model human vein grafts, with regard to their surgical anastomoses as well as the distribution, composition and extent of neointimal hyperplasia within the grafts.12. Sources of graft-extrinsic neointimal cells in our murine model ...
This thesis investigates the principal factors responsible for early failure of femorodistal vein grafts. Chapter 1 provides an overview of severe lower limb ischaemia which is their principal indication. Chapter 2 outlines the role of surgery in the management of the severely ischaemic limb, concentrating on the development of distal bypass using autogenous vein. Chapter 3 considers the multiple causes of vein graft failure, concentrating on the early period and includes an account of currently employed methods designed to reduce the problem. Chapter 4 is a retrospective review of the results of 130 in situ vein grafts performed at Leicester Royal Infirmary in the 8 year period prior to the commencement of this study. The primary early failure rate was 30%, with two thirds of patients undergoing amputation. Chapter 5 outlines the methods used in a series of 42 patients undergoing distal vein bypass. Preoperative assessment included arteriography and 3 methods using Doppler ultrasound. Doppler ...
To the editor: I am responding to a statement made by Farry and associates in a recent case report ("Development of Atherosclerosis in Saphenous Vein Coronary Bypass Graft," Ann Intern Med 85:478-479, 1976).. The authors state that the occurrence of atherosclerosis in aortocornary saphenous vein bypass grafts had not been described before their report. This is not true; our group in Milwaukee has previously reported several such instances (see references below). ...
Orlando, Fla.The addition of clopidogrel to aspirin did not lead to a significant reduction in vein graft intimal hyperplasia during the first year after CABG, according to the CASCADE trial presented Monday during the late-breaking clinical trials session at the 2009 American Heart Association conference.
Patients who develop in-stent restenosis constitute a peculiar technical challenge for both interventional cardiologists and cardiac surgeons. Indeed, once anatomical and technical factors have been ruled out, the occurrence of stent failure can identify a subset of patients with particularly aggressive coronary atherosclerosis in whom successful revascularization can be difficult to achieve using either percutaneous or surgical methods. In fact, in the cardiology literature, there is consistent evidence that the percutaneous retreatment of these cases leads to suboptimal clinical results and is associated with an high risk of additional restenosis or occlusion.1-4 Although this issue has not been specifically investigated in surgical series, it is at least likely that even coronary bypass conduits can be damaged by the aggressive atherosclerotic process and develop accelerated graft disease and failure.. The present protocol was conceived to investigate the results of surgical revascularization ...
A person with severely diseased arteries in the leg(s), can experience pain on walking only short distances (critical claudication), pain at rest, or death of tissues in the leg. When the main thigh artery has a long blockage, the best option is to insert a bypass to carry the blood from an artery with good blood flow to the affected artery below the block. Bypass is intended to save limbs that might otherwise require amputation. The different types of material available to create the bypass include the persons own vein (autologous vein), human umbilical vein (HUV) and synthetic materials polytetrafluoroethylene (PTFE) or Dacron, alone or with the blood thinning agent heparin bonded to the inside of the graft. It has been clear for some time that bypass grafts extending to below the knee do not remain patent with good blood flow as well as do above the knee grafts. The aim of this review was to determine the most effective type of material. We identified 13 randomised controlled trials that ...
The findings of ST in the SYNTAX trial are notable in that early (,30 days) and late/very late ARC definite ST (,30 days) were associated with short-term and long-term mortality. It is important to emphasize that the actual causes of death are multifactorial and not easily directly attributed to ST. For example, although lack of post-procedural antiplatelet therapy was the strongest independent predictor of ST (Table 3), a recent substudy of the SYNTAX trial showed that this was of multifactorial origin (9). Factors precluding antiplatelet administration were reported to include gastrointestinal bleeding, retroperitoneal bleeding from procedure-related femoral vascular access, coronary perforation, or following surgical bailout for PCI-related complications. Consequently, directly attributing ST to mortality is difficult, although it is clear there was a strong causal link.. In addition, ST most frequently occurred in the left main and proximal vasculature (,70% of cases). Accordingly, the ...
We can assume that the cellular content and proportions of different cell types in the HSCT graft are important in safe and efficient HSCT, as is also the spectrum of cytokines the cells secrete. However, there are no systematic studies on the immunological content of clinical HSCT grafts. In current HSCT protocols, the cell and cytokine profile of the graft is not characterized.. In the project we systematically characterise the immune cell profiles of clinical HSCT grafts and study their associations with the outcome of HSCT. From all grafts we estimate the numbers of the following cell populations ...
Percutaneous coronary intervention of degenerated saphenous vein grafts remains relatively high risk when compared to native vessel interventions, despite advances in pharmacotherapy and embolic protection. This article discusses the phenomenon of distal embolization that seems to plague saphenous vein graft interventions, reviews device-based strategies for embolic protection, and offers a perspective on the utility of percutaneous saphenous vein graft intervention in both elective and acute settings.. ...
TY - JOUR. T1 - Contemporary use of embolic protection devices in saphenous vein graft interventions. T2 - Insights from the stenting of saphenous vein grafts trial. AU - Badhey, Neeraj. AU - Lichtenwalter, Christopher. AU - de Lemos, James A. AU - Roesle, Michele. AU - Obel, Owen. AU - Addo, Tayo A. AU - Haagen, Donald. AU - Abdel-Karim, Abdul Rahman. AU - Saeed, Bilal. AU - Bissett, Joseph K.. AU - Sachdeva, Rajesh. AU - Voudris, Vassilios V.. AU - Karyofillis, Panagiotis. AU - Kar, Biswajit. AU - Rossen, James. AU - Fasseas, Panayotis. AU - Berger, Peter B.. AU - Banerjee, Subhash. AU - Brilakis, Emmanouil S. PY - 2010/8/1. Y1 - 2010/8/1. N2 - Background: We sought to evaluate the contemporary use of embolic protection devices (EPDs) in saphenous vein graft (SVG) interventions. Methods: We examined EPD use in the stenting of saphenous vein grafts (SOS) trial, in which 80 patients with 112 lesions in 88 SVGs were randomized to a bare metal stent (39 patients, 43 grafts, and 55 lesions) or ...
Coronary artery bypass grafting is an effective treatment for myocardial ischaemia and is particularly important in patients with multivessel disease and diabetes. However, up to 40% of saphenous vein grafts will occlude within 10 years of surgery. T
The saphenous vein, which runs from the ankle to the groin along the inside of the leg, is commonly used as a graft for people undergoing a CABG surgery. The vein is removed from the leg and reattached to the heart to create a detour around the blocked part of a coronary artery. Following this procedure, many people are prescribed aspirin as a way to increase the chance that the graft procedure will be successful. However, saphenous vein graft failure may still occur in some people, indicating a need to understand why this happens and who might be at risk for graft failure. Thrombin, a protein involved in the blood clotting process, is somehow related to aspirin resistance, abnormalities in blood flow, and cell disruption within the saphenous vein, all factors thought to increase the risk of graft failure. The purpose of this study is to evaluate the likelihood that a burst in thrombin contributes to graft failure in people who have recently undergone a CABG procedure using the saphenous ...
The saphenous vein, which runs from the ankle to the groin along the inside of the leg, is commonly used as a graft for people undergoing a CABG surgery. The vein is removed from the leg and reattached to the heart to create a detour around the blocked part of a coronary artery. Following this procedure, many people are prescribed aspirin as a way to increase the chance that the graft procedure will be successful. However, saphenous vein graft failure may still occur in some people, indicating a need to understand why this happens and who might be at risk for graft failure. Thrombin, a protein involved in the blood clotting process, is somehow related to aspirin resistance, abnormalities in blood flow, and cell disruption within the saphenous vein, all factors thought to increase the risk of graft failure. The purpose of this study is to evaluate the likelihood that a burst in thrombin contributes to graft failure in people who have recently undergone a CABG procedure using the saphenous ...
HistoryA 48-year-old man underwent three-vessel aortocoronary bypass graft for unstable angina and high-grade occlusive coronary artery disease. Postoperatively
Background Saphenous vein grafts develop an aggressive atherosclerotic process and the efficacy of drug eluting stents (DES) in treating saphenous vein graft (SVG) lesions has not been convincingly demonstrated. The aim of this study was to review and analyze the current literature for controlled studies comparing DES versus bare metal stents (BMS) for treatment of SVG stenoses. Methodology/Principal Findings We searched several scientific databases and conference proceedings up to March 15, 2010 for controlled studies comparing target vessel revascularization (TVR) between DES and BMS. Summary odds ratios (OR) for the primary endpoint TVR and secondary endpoints infarction, stent thrombosis and death were calculated using random-effect models. A total of 29 studies (3 randomized controlled trials RCT) involving 7549 (202 in RCT) patients were included. The need for target vessel revascularization in the DES group tended to be lower compared to BMS for the 3 RCT (OR 0.50 [0.24-1.00]; p = 0.051) and for
Aneurysmatic degeneration of saphenous vein coronary artery grafts is a rare complication that generally appears late. Most of these cases are asymptomatic, although they may also be accompanied by angina, heart attack or dyspnea. The suspected diagnosis should be made when a mediastinal mass is discovered in the thoracic x-ray of a patient with a history of coronary revascularization. A computerized tomography and coronary angiography should be performed in order to confirm the diagnosis.. Due to the significant morbidity and mortality risk inherent to the risk of rupture, embolization or heart attack, surgery to remove or exclude the aneurysm should be considered as definitive treatment.. ...
The use of embolic protection devices (EPDs) when treating coronary saphenous vein bypass grafts, performing carotid arterial stenting and treating acute coronary syndromes is well accepted.
Despite the fact that stents have improved the outcome of percutaneous intervention of obstructed vein grafts (2,3), prognosis of patients undergoing this procedure is still poor (4,12). Targets to improve intervention in saphenous vein grafts are to inhibit distal embolization of atherosclerotic debris (13)and to reduce restenosis rate, which is elevated compared with native vessels (2,4,14). Thus, it was intriguing to hypothesize that a stent covered with a membrane would seal the lumen and prevent protrusion of proliferating tissue and, thereby, reduce microembolization and restenosis rate. However, the present trial does not reveal a benefit of the PTFE-membrane-covered Jostent Stentgraft compared with the conventional stent used (Jostent Flex); restenosis rate, the primary end point, did not significantly differ between the Stentgraft (29%) and the conventional stent group (20%). In addition, acute complications and long-term clinical event rate up to 15 months were comparable between the ...
Over a million coronary bypass procedures using human saphenous vein (HSV) are performed yearly worldwide. Nearly half of these grafts fail over a period of 12...
Dr Joye believes that there are many other possible applications for cryoplasty in the vascular field. Joyce said: "We are investigating coronary applications for native coronary areas, bypass grafts and for vulnerable plaque treatment. In the peripheral arena we are exploring applications for limb salvage and dialysis graft treatment to name a few.". One concern over cryoplasty is its anticipated cost compared to other procedures. "A cryoplasty balloon will certainly cost more than an existing PTA balloon. However, by contrast, it will cost significantly less than a drug-eluting stent," explained Joye.. Joye contends, "In the real world, as at least half of lesions are dilated and stented, the cost per procedure is actually significantly less with cryoplasty" He added, "The more complex the lesion, the greater the cost advantage, because instead of the incremental cost of each successive stent, cryoplasty has a nominal cost associated with each inflation". As an example he stated, " A 30cm ...
Semantic Scholar extracted view of Atherosclerosis and aneurysm formation in a saphenous vein-graft. by Alberto G de la Rocha et al.
I have another one that I think I have, but want to check to make sure. Any help would be greatly appreciated. Indications: A 70 year old with history
Is it possible that youre overpaying for biological surgical grafts? When you purchase grafts direct from Select Surgical Technologies, youll cut out t
-Vein graft intimal hyperplasia, due to smooth muscle cell (SMC) proliferation, remains a limiting factor in long-term vein graft patency. Increased superoxide production regulates SMC mitogenesis and contributes to reduced NO bioactivity in systemic models of vascular disease. We compared superoxide production in experimental venous bypass grafts with ungrafted veins and determined its enzymatic sources and cellular localization. Vascular superoxide production was measured in vein grafts and control jugular veins obtained from normocholesterolemic rabbits undergoing jugular vein-carotid artery interposition bypass grafting. Surgical isolation of the contralateral jugular vein, without bypass grafting, provided an additional control for the effects of surgical manipulation. Superoxide production was increased 3-fold in vein grafts compared with control veins. Systematic stimulation and inhibition of specific oxidases revealed that the major source of increased vein graft superoxide production was a
Objective: The saphenous vein is the most commonly used graft in coronary artery bypass surgery, since no suitable arterial graft is available. However, the frequency of late graft failure is a cause for research into graft protection. The objective of this study was to investigate the effect of synthetic adhesive cyanoacrylate administration on the saphenous vein graft for preventing vascular damage due to internal pressure on the graft. Methods: In this study we enrolled 20 volunteer subjects who had undergone coronary artery bypass surgery and who had excess saphenous vein grafts. Perivascular cyanoacrylate was administered to one of two saphenous vein grafts explanted from each patient. The other saphenous vein graft from each patient was not treated and was used as the control. A model of the arterial system was created using a saphenous vein cardiopulmonary bypass system. Circulation was maintained at 120 mmHg for 45 minutes. Afterwards, the grafts were subjected to histopathological examination.
A 73 year old woman presented with angina 22 years after saphenous vein grafts. All three grafts were in excellent condition, with the exception of a severe stenosis in the proximal portion of the circumflex graft (panel A). For elective percutaneous coronary intervention (PCI), a FilterWire distal protection device was deployed in the body of the graft before pre-dilatation with a 2.5 × 15 mm Maverick balloon. Aiming to minimise the risk of distal embolisation, a (self expanding nitinol) Symbiot polymer covered stent (4.0 × 20 mm) was deployed (panel B). These stents require post-inflation to optimise deployment. Following in-stent inflation (4.0 × 15 mm Extensor) a new filling defect (white arrow) was immediately apparent within the stent at its proximal end (panel C). Filling defects (white arrows) were also present within the FilterWire device (black arrows) (panel C). The in-stent debris was presumed to be material extruded from the proximal margin of the covered stent after high ...
BACKGROUND: Saphenous vein graft disease remains a major limitation of coronary artery bypass graft surgery. The process of saphenous vein intimal hyperplasia begins just days after surgical revascularization, setting the stage for graft atherosclero
Objective: Physiological reaction to competitive flow is considered as the primary mechanism of arterial graft occlusion. Reopening of graft lumen had been also reported, but details remain unknown. We sought to delineate the effect of management of the moderately stenotic targets on the occurrence of competitive flow and clinical results. Methods: Clinical records and angiograms of 3263 bypass grafts in 852 patients, who underwent off-pump coronary revascularization using the internal thoracic artery (ITA) and radial artery without aortic manipulation since 2000, were examined. Dominant flow direction was graded as antegrade, competitive, and no flow (occlusion). Late angiography was performed in 157 patients with 561 bypass grafts for clinical reasons. The follow-up period was 55.5 ± 31.1 months. Results: The early graft patency rate was 98.0% (3197/3263). The rate of antegrade flow was 91.5% (2986/3263), while competitive flow was detected in 6.5% (211/3263). The actuarial patency rates of ...
This was a randomized controlled multicenter clinical trial that enrolled patients with a previous coronary artery bypass graft who had developed at least 1 intermediate nonobstructive SVG lesion (30%-60% diameter stenosis by visual estimation). Patients were randomized (1:1) to DES implantation (SVG-DES) or medical treatment (SVG-MT) of the target SVG lesion. The primary efficacy outcome was the first occurrence of MACE defined as the composite of cardiac death, myocardial infarction, or coronary revascularization related to the target SVG during the duration of follow-up (minimum of 2 years). Secondary efficacy outcomes included MACE related to the target SVG lesion and overall MACE. A total of 125 patients (mean age 70±9 years, 87% men) were included, with a mean time from coronary artery bypass graft of 12±5 years. Sixty and 65 patients were allocated to the SVG-DES and SVG-MT groups, respectively. There were no events related to the target SVG at 30 days. After a median follow-up of 3.4 ...
SCVS 2018 Abstracts: Complete vs. Partial Excision of Infected Arteriovenous Grafts: Does Remnant Graft Material Impact Outcomes?
Free, official coding info for 2018 ICD-10-CM I70.42 - includes detailed rules, notes, synonyms, ICD-9-CM conversion, index and annotation crosswalks, DRG grouping and more.
Free, official coding info for 2018 ICD-10-CM I70.40 - includes detailed rules, notes, synonyms, ICD-9-CM conversion, index and annotation crosswalks, DRG grouping and more.
A percutaneous system for bypassing a restriction in a native vessel of a mammal having an aorta includes providing a graft having a body portion with a first end, a second end and a lumen therebetween. An aperture is formed in the aorta. The graft is inserted into the aorta and the first end of the graft is connected to the aorta about the aperture in the aorta. An aperture is then formed in the native vessel distal of the restriction. The second end of the graft is connected to the native vessel about the aperture therein such that the lumen in the graft communicates with the aorta and the native vessel.
Over time, off-pump bypass surgery grafts may fail. This eMedTV resource discusses graft failure and off-pump bypass surgery, including how long grafts typically last and tips that can help delay graft failure after surgery.
AngioGRAFT® cryopreserved vascular allografts are the safe choice for managing vascular reconstruction. [1]. In peripheral bypass surgery, LifeNet Health femoral and saphenous vessel allografts provide an effective clinical option. When bypassing stenosed vascular segments in the treatment of peripheral vascular disease, or in CABG procedures, acceptable native vessels are often not available. LifeNet Health cryopreserved vessels are a natural solution for peripheral bypass procedures and reconstruction. When confronting failing A/V access grafts, consider LifeNet Health allografts as an ideal natural solution for dialysis access and the replacement of infected synthetic dialysis grafts.. Learn about our newest life-saving graft. AngioGraft Aortoiliac Artery. [2]. ...
Inflammation plays a major role in vascular diseases such as atherosclerosis, vein graft stenosis and proliferative restenosis following angioplasty and stent p...
451 In order to present an accurate picture of the rate of thrombosis, findings of both the entire group of 193 patients with limited studies and the followed group of 131 patients have been presented. Ten thromboses are known to have existed in the 62 patients lost to followup. The number of thromboses in the amputated patients is unknown so the rate of thrombosis is figured for only the living unamputated patients. When rates of thrombosis of the short-term followed and late followed groups are compared, they are found to be almost identical (tables 5 and 6). If these findings are any criteria to the most satisfactory methods of repair, then the preferred methods are, in order, lateral repair, direct anastomosis, autogenous vein graft and homologous artery graft. However, it must be borne in mind that lateral repair was used for only the simplest lacerations and the more extensive the wound the more complicated the repair.. Lateral repair should be reserved for only minor, clean-cut ...
A graft system is provided that includes either a support ring or a support sleeve that is used in providing transitional support to either an end or a side of a graft or a host vessel. The support ring is provided with a generally cylindrical wall and defining a passageway that is adapted for receiving an end of a vein graft or an end of a host vessel. The support ring has a first end and a second end, with the thickness of the wall being greater at the first end than at the second end. The support sleeve is provided with a first side edge, a second side edge, and an opening. The support sleeve surrounds a side opening of a graft or host vessel so that the opening of the support sleeve is aligned with the side opening of the graft or host vessel. The thickness of the support sleeve is greater at the opening than at the first and second side edges.